编者按：2024年ESMO ASIA大会于12月6日至8日在新加坡举行，吸引了亚洲乃至世界肿瘤学界的顶尖学者和研究专家，同时也分享了众多泌尿肿瘤研究成果。本届大会上，复旦大学附属肿瘤医院叶定伟教授团队的多项研究入选，凸显了中国泌尿肿瘤领域的进步与发展。本刊特别整理，以飨读者。

1

英文标题：Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase 3 CheckMate 901 trial

中文标题：纳武利尤单抗联合吉西他滨-顺铂（GC）对比单用GC治疗未经治的不可切除或转移性尿路上皮癌（u/mUC）患者：来自3期CheckMate 901试验的中国人群分析结果

2

英文标题：Unveiling the Impact of Tertiary Lymphoid Structures on Immunotherapeutic Responses of Renal Cell Carcinoma

中文标题：揭示三级淋巴结构对肾细胞癌免疫治疗缓解情况的影响

3

英文标题：Comparative genomic and clinical features between malignant renal epithelioid angiomyolipoma and benign angiomyolipoma（Anwaier Aihetaimujiang）

中文标题：恶性肾上皮样血管平滑肌脂肪瘤与良性血管平滑肌脂肪瘤的基因组和临床特征比较

4

英文标题：Multi-Omics Data Reveal Potential Therapeutic Targets for Translational Renal Cell Carcinoma: Results from the Largest Retrospective Integrated Cohort

中文标题：多组学数据揭示易位性肾细胞癌的潜在治疗靶点：来自最大回顾性综合队列的结果

5

英文标题：Identification of Translational Renal Cell Carcinomas Based on Transformer Model and Pathogenomic Data: A Multicenter Study

中文标题：根据转化模型和病理组学数据识别易位性肾细胞癌：一项多中心研究

6

英文标题：A prospective, single-arm clinical study of Disitamab Vedotin (DV) combined with Toripalimab for kidney sparing in solitary kidney or renal insufficiency or bilateral multiple upper urinary tract urothelial carcinoma (UTUC)

中文标题：一项前瞻性、单臂临床研究，探讨维迪西妥单抗联合特瑞普利单抗保肾治疗单肾或肾功能不全或双侧多发性上尿路尿路上皮癌（UTUC）患者

7

英文标题：Patient-reported outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Results from the China ARCHES trial

中文标题：转移性激素敏感性前列腺癌（mHSPC）的患者报告结局：中国ARCHES试验结果

8

英文题目：Heterogeneity of tertiary lymphoid structures predicts distinct malignancy and immune microenvironment in prostate cancer

中文题目：通过三级淋巴结构异质性预测前列腺癌的不同恶性程度和免疫微环境

参考文献：

1. Dingwei Ye, et al. 277P - Nivolumab (NIVO) plus gemcitabine-cisplatin (GC) vs GC alone for previously untreated unresectable or metastatic urothelial carcinoma (u/mUC): Chinese population analysis results from the phase III CheckMate 901 trial. ESMO ASIA 2024.

2. Dingwei Ye, et al. 293P - Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of renal cell carcinoma. ESMO ASIA 2024.

3. Anwaier Aihetaimujiang, et al. 297P - Comparative genomic and clinical features between malignant renal epithelioid angiomyolipoma and benign angiomyolipoma. ESMO ASIA 2024.

4. Hailiang Zhang, et al. 332P - Multi-omics data reveal potential therapeutic targets for translational renal cell carcinoma: Results from the largest retrospective integrated cohort. ESMO ASIA 2024.

5. Dingwei Ye, et al. 333P - Identification of translational renal cell carcinomas based on transformer model and pathogenomic data: A multicenter study. ESMO ASIA 2024.

6. Xi Tian, et al. 334TiP - A prospective, single-arm clinical study of disitamab vedotin (DV) combined with toripalimab for kidney sparing in solitary kidney or renal insufficiency or bilateral multiple upper urinary tract urothelial carcinoma (UTUC) ESMO ASIA 2024.

7. Xiaolin Lu, et al. 345P - Patient-reported outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Results from the China ARCHES trial. ESMO ASIA 2024.

8. Wenhao Xu, et al. 353P - Heterogeneity of tertiary lymphoid structures predicts distinct malignancy and immune microenvironment in prostate cancer ESMO ASIA 2024.

（来源：《肿瘤瞭望-泌尿时讯》编辑部）

声 明

凡署名原创的文章版权属《肿瘤瞭望-泌尿时讯》所有，欢迎分享、转载（开白可后台留言）。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

温馨提示

添加小助手请备注“泌尿”